About Orbital Therapeutics
Orbital Therapeutics focuses on developing RNA-based medicines, specifically targeting areas like vaccines, immunomodulation, and protein replacement. The company utilizes RNA technology, advanced delivery methods, data science, and automation to create a platform for a wide range of therapeutic applications. Unlike many competitors, Orbital Therapeutics does not work with small interfering RNA, which sets it apart in the RNA medicine space. The goal is to enhance global health by harnessing RNA medicines to treat diseases in innovative ways that were not possible before. Revenue is generated through the sale of these RNA-based therapies to healthcare providers, who then administer them to patients.
San Francisco, CaliforniaHeadquarters
2022Year Founded
$262.6MTotal Funding
SERIES_ACompany Stage
Biotechnology, HealthcareIndustries
51-200Employees
Risks
Increased competition from companies like Moderna and BioNTech could challenge Orbital.
Potential regulatory hurdles could delay RNA-based therapy product approvals.
Rapid technological advancements may require continuous R&D investment, straining resources.
Differentiation
Orbital Therapeutics focuses on RNA-based medicines excluding small interfering RNA.
The company integrates RNA technology with delivery techniques, data analytics, and automation.
Orbital's initial focus is on vaccines, immunomodulation, and protein replacement.
Upsides
RNA-based vaccines are gaining traction for rapid response to emerging diseases.
Advancements in lipid nanoparticle technology enhance RNA therapeutic delivery efficiency.
The trend of personalized medicine increases demand for RNA-based therapies.
Funding
Total raised$262.64 M
Latest valuation$1.35 B
StageSERIES_A